Regulation of Type IV Pili contributes to surface behaviors of historical and epidemic strains of Clostridium difficile

Journal of Bacteriology

Volumn 198, Issue 3, 2016, Pages 565-577

  Purcell, Erin B ^a   McKee, Robert W ^a   Bordeleau, Eric ^b   Burrus, Vincent ^b   Tamayo, Rita ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADHESIN; CYCLIC DIGUANYLATE; GUANOSINE PHOSPHATE; PROTEIN TYPE IV PILUS; UNCLASSIFIED DRUG; BACTERIAL PROTEIN;

ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM PILUS; BIOFILM; BIOSYNTHESIS; CONTROLLED STUDY; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSCRIPTION; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PHENOTYPE; PILIN A1 GENE; PRIORITY JOURNAL; PROMOTER REGION; RIBOSWITCH; TRANSCRIPTION INITIATION; UPREGULATION; CLASSIFICATION; FIMBRIA; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOGENICITY; PHYSIOLOGY; VIRULENCE;

BACTERIAL PROTEINS; BIOFILMS; CLOSTRIDIUM DIFFICILE; FIMBRIAE, BACTERIAL; GENE EXPRESSION REGULATION, BACTERIAL; PROMOTER REGIONS, GENETIC; VIRULENCE;

EID: 84957707432     PISSN: 00219193     EISSN: 10985530     Source Type: Journal    
DOI: 10.1128/JB.00816-15     Document Type: Article

References (79)

1. Miller M. 2010. Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection. Expert Opin Pharmacother 11:1569-1578. http://dx.doi.org/10.1517/14656566.2010.485614.
2. Dubberke ER, Gerding DN, Classen D, Arias KM, Podgorny K, Anderson DJ, Burstin H, CalfeeD P, Coffin SE, Fraser V, Griffin FA, Gross P, Kaye KS, Klompas M, Lo E, Marschall J, Mermel LA, Nicolle L, Pegues DA, Perl TM, Saint S, Salgado CD, Weinstein RA, Wise R, Yokoe DS. 2008. Strategies to Prevent Clostridium difficile Infections in Acute Care Hospitals. Infect Control Hosp Epidemiol 29:S81-S92. http://dx.doi.org/10.1086/591065.
3. Bartlett JG. 2010. Clostridium difficile: progress and challenges. Ann N Y Acad Sci 1213:62-69. http://dx.doi.org/10.1111/j.1749-6632.2010.05863.x.
4. Deakin LJ, Clare S, Fagan RP, Dawson LF, Pickard DJ, West MR, Wren BW, Fairweather NF, Dougan G, Lawley TD. 2012. The Clostridium difficile spo0A gene is a persistence and transmission factor. Infect Immun 80:2704-2711. http://dx.doi.org/10.1128/IAI.00147-12.
5. Sorg JA, Sonenshein AL. 2008. Bile salts and glycine as cogerminants for Clostridium difficile spores. J Bacteriol 190:2505-2512. http://dx.doi.org/10.1128/JB.01765-07.
6. Howerton A, Ramirez N, Abel-Santos E. 2011. Mapping interactions between germinants and Clostridium difficile spores. J Bacteriol 193:274-282 http://dx.doi.org/10.1128/JB.00980-10.
7. McCollum DL, Rodriguez JM. 2012. Detection, treatment, and prevention of Clostridium difficile infection. Clin Gastroenterol Hepatol 10:581-592 http://dx.doi.org/10.1016/j.cgh.2012.03.008.
8. Voth DE, Ballard JD. 2005. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 18:247-263. http://dx.doi.org/10.1128/CMR.18.2.247-263.2005.
9. Kuipers EJ, Surawicz CM. 2008. Clostridium difficile infection. Lancet 371:1486-1488. http://dx.doi.org/10.1016/S0140-6736(08)60635-2.
10. Denève C, Janoir C, Poilane I, Fantinato C, Collignon A. 2009. New trends in Clostridium difficile virulence and pathogenesis. Int J Antimicrob Agents 33:S24-S28. http://dx.doi.org/10.1016/S0924-8579(09)70012-3.
11. Drekonja DM, Butler M, MacDonald R, Bliss D, Filice GA, Rector TS, Wilt TJ. 2011. Comparative effectiveness of Clostridium difficile treatments: a systematic review. Ann Intern Med 155:839-847. http://dx.doi.org/10.7326/0003-4819-155-12-201112200-00007.
12. Stabler RA, He M, Dawson L, Martin M, Valiente E, Corton C, Lawley TD, Sebaihia M, Quail MA, Rose G, Gerding DN, Gibert M, PopoffMR, Parkhill J, Dougan G, Wren BW. 2009. Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome Biol 10:R102. http://dx.doi.org/10.1186/gb-2009-10-9-r102.
13. He M, Miyajima F, Roberts P, Ellison L, Pickard DJ, Martin MJ, Connor TR, Harris SR, Fairley D, Bamford KB, D'Arc S, Brazier J, Brown D, Coia JE, Douce G, Gerding D, Kim HJ, Koh TH, Kato H, Senoh M, Louie T, Michell S, Butt E, Peacock SJ, Brown NM, Riley T, Songer G, Wilcox M, Pirmohamed M, Kuijper E, Hawkey P, Wren BW, Dougan G, Parkhill J, Lawley TD. 2013. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet 45:109-113 http://dx.doi.org/10.1038/ng.2478.
14. Smits WK. 2013. Hype or hypervirulence: a reflection on problematic C. difficile strains. Virulence 4:592-596. http://dx.doi.org/10.4161/viru.26297.
15. Perelle S, Gibert M, Bourlioux P, Corthier G, PopoffMR. 1997. Production of a complete binary toxin (actin-specific ADP-ribosyltransferase) by Clostridium difficile CD196. Infect Immun 65:1402-1407.
16. Scaria J, Mao C, Chen J-W, McDonough SP, Sobral B, Chang Y-F. 2013. Differential stress transcriptome landscape of historic and recently emerged hypervirulent strains of Clostridium difficile strains determined using RNA-seq. PLoS One 8:e78489. http://dx.doi.org/10.1371/journal.pone.0078489.
17. Romling U, Galperin MY, Gomelsky M. 2013. Cyclic di-GMP: the first 25 years of a universal bacterial second messenger. Microbiol Mol Biol Rev 77:1-52. http://dx.doi.org/10.1128/MMBR.00043-12.
18. Sebaihia M, Wren BW, Mullany P, Fairweather NF, Minton N, Stabler R, Thomson NR, Roberts AP, Cerdeno-Tarraga AM, Wang H, Holden MT, Wright A, Churcher C, Quail MA, Baker S, Bason N, Brooks K, Chillingworth T, Cronin A, Davis P, Dowd L, Fraser A, Feltwell T, Hance Z, Holroyd S, Jagels K, Moule S, Mungall K, Price C, Rabbinowitsch E, Sharp S, Simmonds M, Stevens K, Unwin L, Whithead S, Dupuy B, Dougan G, Barrell B, Parkhill J. 2006. The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. Nat Genet 38:779-786. http://dx.doi.org/10.1038/ng1830.
19. Bordeleau E, Fortier LC, Malouin F, Burrus V. 2011. c-di-GMP turnover in Clostridium difficile is controlled by a plethora of diguanylate cyclases and phosphodiesterases. PLoS Genet 7:e1002039. http://dx.doi.org/10.1371/journal.pgen.1002039.
20. Gao X, Dong X, Subramanian S, Matthews PM, Cooper CA, Kearns DB, Dann CE. 2014. Engineering of Bacillus subtilis strains to allow rapid characterization of heterologous diguanylate cyclases and phosphodiesterases. Appl Environ Microbiol 80:6167-6174. http://dx.doi.org/10.1128/AEM.01638-14.
21. Purcell EB, McKee RW, McBride SM, Waters CM, Tamayo R. 2012. Cyclic diguanylate inversely regulates motility and aggregation in Clostridium difficile. J Bacteriol 194:3307-3316. http://dx.doi.org/10.1128/JB.00100-12.
22. McKee RW, Mangalea MR, Purcell EB, Borchardt EK, Tamayo R. 2013. The second messenger cyclic di-GMP regulates Clostridium difficile toxin production by controlling expression of sigD. J Bacteriol 195:5174-5185. http://dx.doi.org/10.1128/JB.00501-13.
23. van Eijk E, Anvar S, Browne HP, Leung W, Frank J, Schmitz AM, Roberts AP, Smits W. 2015. Complete genome sequence of the Clostridium difficile laboratory strain 630Δerm reveals differences from strain 630, including translocation of the mobile element CTn 5. BMC Genomics 16:31. http://dx.doi.org/10.1186/s12864-015-1252-7.
24. Bordeleau E, Purcell EB, Lafontaine DA, Fortier LC, Tamayo R, Burrus V. 2015. Cyclic di-GMP riboswitch-regulated type IV pili contribute to aggregation of Clostridium difficile. J Bacteriol 197:819-832. http://dx.doi.org/10.1128/JB.02340-14.
25. Soutourina OA, Monot M, Boudry P, Saujet L, Pichon C, Sismeiro O, Semenova E, Severinov K, Le Bouguenec C, Coppee JY, Dupuy B, Martin-Verstraete I. 2013. Genome-wide identification of regulatory RNAs in the human pathogen Clostridium difficile. PLoS Genet 9:e1003493. http://dx.doi.org/10.1371/journal.pgen.1003493.
26. Piepenbrink KH, Maldarelli GA, de la Pena CF, Mulvey GL, Snyder GA, De Masi L, von Rosenvinge EC, Gunther S, Armstrong GD, Donnenberg MS, Sundberg EJ. 2014. Structure of Clostridium difficile PilJ exhibitsunprecedented divergence from known type IV pilins. J Biol Chem 289: 4334-4345. http://dx.doi.org/10.1074/jbc. M113.534404.
27. Rodgers K, Arvidson CG, Melville S. 2011. Expression of a Clostridium perfringens type IV pilin by Neisseria gonorrhoeae mediates adherence to muscle cells. Infect Immun 79:3096-3105. http://dx.doi.org/10.1128/IAI.00909-10.
28. Varga JJ, Therit B, Melville SB. 2008. Type IV pili and the CcpA protein are needed for maximal biofilm formation by the Gram-positive anaerobic pathogen Clostridium perfringens. Infect Immun 76:4944-4951. http://dx.doi.org/10.1128/IAI.00692-08.
29. Jurcisek JA, Bakaletz LO. 2007. Biofilms formed by nontypeable Haemophilus influenzae in vivo contain both double-stranded DNA and type IV pilin protein. J Bacteriol 189:3868-3875. http://dx.doi.org/10.1128/JB.01935-06.
30. Mattick JS. 2002. Type IV pili and twitching motility. Annu Rev Microbiol 56:289-314. http://dx.doi.org/10.1146/annurev.micro.56.012302.160938.
31. Proft T, Baker EN. 2009. Pili in Gram-negative and Gram-positive bacteria: structure, assembly and their role in disease. Cell Mol Life Sci 66: 613-635. http://dx.doi.org/10.1007/s00018-008-8477-4.
32. Kearns DB. 2010. A field guide to bacterial swarming motility. Nat Rev Microbiol 8:634-644. http://dx.doi.org/10.1038/nrmicro2405.
33. Butler MT, Wang Q, Harshey RM. 2010. Cell density and mobility protect swarming bacteria against antibiotics. Proc Natl Acad Sci U S A 107:3776-3781. http://dx.doi.org/10.1073/pnas.0910934107.
34. Imam S, Chen Z, Roos DS, Pohlschröder M. 2011. Identification of surprisingly diverse type IV pili, across a broad range of Gram-positive bacteria. PLoS One 6:e28919. http://dx.doi.org/10.1371/journal.pone.0028919.
35. Varga JJ, Nguyen V, O'Brien DK, Rodgers K, Walker RA, Melville SB. 2006 Type IV pili-dependent gliding motility in the Gram-positive pathogen Clostridium perfringens and other clostridia. Mol Microbiol 62:680-694 http://dx.doi.org/10.1111/j.1365-2958.2006.05414.x.
36. Mendez M, Huang IH, Ohtani K, Grau R, Shimizu T, Sarker MR. 2008. Carbon catabolite repression of type IV pilus-dependent gliding motility in the anaerobic pathogen Clostridium perfringens. J Bacteriol 190:48-60. http://dx.doi.org/10.1128/JB.01407-07.
37. Sorg JA, Dineen SS. 2009. Laboratory maintenance of Clostridium difficile. Curr Protoc Microbiol Chapter 9:Unit9A.1. doi:http://dx.doi.org/10.1002/9780471729259.mc09a01s12.
38. Heap JT, Kuehne SA, Ehsaan M, Cartman ST, Cooksley CM, Scott JC, Minton NP. 2010. The ClosTron: mutagenesis in Clostridium refined and streamlined. J Microbiol Methods 80:49-55. http://dx.doi.org/10.1016/j.mimet.2009.10.018.
39. Perutka J, Wang W, Goerlitz D, Lambowitz AM. 2004. Use of computerdesigned group II introns to disrupt Escherichia coli DExH/D-box protein and DNA helicase genes. J Mol Biol 336:421-439. http://dx.doi.org/10.1016/j.jmb.2003.12.009.
40. Mullany P, Wilks M, Tabaqchali S. 1991. Transfer of Tn916 and Tn916 delta E into Clostridium difficile: demonstration of a hot-spot for these elements in the C. difficile genome. FEMS Microbiol Lett 63:191-194.
41. Manganelli R, Provvedi R, Berneri C, Oggioni MR, Pozzi G. 1998. Insertion vectors for construction of recombinant conjugative transposons in Bacillus subtilis and Enterococcus faecalis. FEMS Microbiol Lett 168:259-268. http://dx.doi.org/10.1111/j.1574-6968.1998.tb13282.x.
42. Bouillaut L, McBride SM, Sorg JA. 2011. Genetic manipulation of Clostridium difficile. Curr Protoc Microbiol Chapter 9:Unit 9A.2. http://dx.doi.org/10.1002/9780471729259.mc09a02s20.
43. Dapa T, Leuzzi Ng R, Baban YK, Adamo ST, Kuehne R, Scarselli SA, Minton M, Serruto NP, Unnikrishnan DM. 2013. Multiple factors modulate biofilm formation by the anaerobic pathogen Clostridium difficile. J Bacteriol 195:545-555. http://dx.doi.org/10.1128/JB.01980-12.
44. McBride SM, Sonenshein AL. 2011. Identification of a genetic locus responsible for antimicrobial peptide resistance in Clostridium difficile. Infect Immun 79:167-176. http://dx.doi.org/10.1128/IAI.00731-10.
45. Mudrak B, Tamayo R. 2012. The Vibrio cholerae Pst2 phosphate transport system is upregulated in biofilms and contributes to biofilm-induced hyperinfectivity. Infect Immun 80:1794-1802. http://dx.doi.org/10.1128/IAI.06277-11.
46. Dupuy B, Sonenshein AL. 1998. Regulated transcription of Clostridium difficile toxin genes. Mol Microbiol 27:107-120. http://dx.doi.org/10.1046/j.1365-2958.1998.00663.x.
47. Emerson JE, Reynolds CB, Fagan RP, Shaw HA, Goulding D, Fairweather NF. 2009. A novel genetic switch controls phase variable expressiona Clostridium difficile cell wall protein. Mol Microbiol 74: 541-556. http://dx.doi.org/10.1111/j.1365-2958.2009.06812.x.
48. Chan C, Paul R, Samoray D, Amiot NC, Giese B, Jenal U, Schirmer T. 2004 Structural basis of activity and allosteric control of diguanylate cyclase. Proc Natl Acad Sci U S A 101:17084-17089. http://dx.doi.org/10.1073/pnas.0406134101.
49. Paul R, Abel S, Wassmann P, Beck A, Heerklotz H, Jenal U. 2007. Activation of the diguanylate cyclase PleD by phosphorylation-mediated dimerization. J Biol Chem 282:29170-29177. http://dx.doi.org/10.1074/jbc. M704702200.
50. Maldarelli GA, De Masi L, von Rosenvinge EC, Carter M, Donnenberg MS. 2014. Identification, immunogenicity, and cross-reactivity of type IV pilin and pilin-like proteins from Clostridium difficile. Pathog Dis 71:302-314 http://dx.doi.org/10.1111/2049-632X.12137.
51. Melville S, Craig L. 2013. Type IV pili in Gram-positive bacteria. Microbiol Mol Biol Rev 77:323-341. http://dx.doi.org/10.1128/MMBR.00063-12.
52. Murray TS, Kazmierczak BI. 2008. Pseudomonas aeruginosa exhibits sliding motility in the absence of type IV pili and flagella. J Bacteriol 190: 2700-2708. http://dx.doi.org/10.1128/JB.01620-07.
53. Davey ME, O'Toole GA. 2000. Microbial biofilms: from ecology to molecular genetics. Microbiol Mol Biol Rev 64:847-867. http://dx.doi.org/10.1128/MMBR.64.4.847-867.2000.
54. McCarter L, Hilmen M, Silverman M. 1988. Flagellar dynamometer controls swarmer cell differentiation of V. parahaemolyticus. Cell 54:345-351 http://dx.doi.org/10.1016/0092-8674(88)90197-3.
55. Belas R, Suvanasuthi R. 2005. The ability of Proteus mirabilis to sense surfaces and regulate virulence gene expression involves FliL, a flagellar basal body protein. J Bacteriol 187:6789-6803. http://dx.doi.org/10.1128/JB.187.19.6789-6803.2005.
56. Li G, Brown PJ, Tang JX, Xu J, Quardokus EM, Fuqua C, Brun YV. 2012 Surface contact stimulates the just-in-time deployment of bacterial adhesins. Mol Microbiol 83:41-51. http://dx.doi.org/10.1111/j.1365-2958.2011.07909.x.
57. Cairns LS, Marlow VL, Bissett E, Ostrowski A, Stanley-Wall NR. 2013. A mechanical signal transmitted by the flagellum controls signalling in Bacillus subtilis. Mol Microbiol 90:6-21. http://dx.doi.org/10.1111/mmi.12342.
58. Ellison C, Brun YV. 2015. Mechanosensing: a regulation sensation. Curr Biol 25:R113-R115. http://dx.doi.org/10.1016/j.cub.2014.12.026.
59. Siryaporn A, Kuchma SL, O'Toole GA, Gitai Z. 2014. Surface attachment induces Pseudomonas aeruginosa virulence. Proc Natl Acad SciUSA 111:16860-16865. http://dx.doi.org/10.1073/pnas.1415712111.
60. Karjalainen T, Barc MC, Collignon A, Trollé S, Boureau H, Cotte-Laffitte J, Bourlioux P. 1994. Cloning of a genetic determinant from Clostridium difficile involved in adherence to tissue culture cells and mucus. Infect Immun 62:4347-4355.
61. Eveillard M, Fourel V, Bare M-C, Kernéis S, Coconnier M-H, Karjalainen T, Bourlioux P, Servin AL. 1993. Identification and characterization of adhesive factors of Clostridium difficile involved in adhesion to human colonic enterocyte-like Caco-2 and mucus-secreting HT29 cells in culture. Mol Microbiol 7:371-381. http://dx.doi.org/10.1111/j.1365-2958.1993.tb01129.x.
62. Cerquetti M, Serafino A, Sebastianelli A, Mastrantonio P. 2002. Binding of Clostridium difficile to Caco-2 epithelial cell line and to extracellular matrix proteins. FEMS Immunol Med Microbiol 32:211-218. http://dx.doi.org/10.1111/j.1574-695X.2002.tb00556.x.
63. Borriello SP, Welch AR, Barclay FE, Davies HA. 1988. Mucosal association by Clostridium difficile in the hamster gastrointestinal tract. J Med Microbiol 25:191-196. http://dx.doi.org/10.1099/00222615-25-3-191.
64. Gomez-Trevino M, Boureau H, Karjalainen T, Bourlioux P. 1996. Clostridium dificile adherence to mucus: results of an in vivo and ex vivo assay. Microb Ecol Health Dis 9:329-334.
65. Borriello SP. 1979. Clostridium difficile and its toxin in the gastrointestinal tract in health and disease. Res Clin Forums 1:33-35.
66. Goulding D, Thompson H, Emerson J, Fairweather NF, Dougan G, Douce GR. 2009. Distinctive profiles of infection and pathology in hamsters infected with Clostridium difficile strains 630 and B1. Infect Immun 77:5478-5485. http://dx.doi.org/10.1128/IAI.00551-09.
67. Lawley TD, Clare S, Walker AW, Goulding D, Stabler RA, Croucher N, Mastroeni P, Scott P, Raisen C, Mottram L, Fairweather NF, Wren BW, Parkhill J, Dougan G. 2009. Antibiotic treatment of Clostridium difficile carrier mice triggers a supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts. Infect Immun 77: 3661-3669. http://dx.doi.org/10.1128/IAI.00558-09.
68. Finlay BB, Falkow S. 1989. Common themes in microbial pathogenicity. Microbiol Rev 53:210-230.
69. Parker KJ, Huang SR, Musulin RA, Lerner RM. 1990. Tissue response to mechanical vibrations for "sonoelasticity imaging." Ultrasound Med Biol 16:241-246.
70. Cha SW, Kim IY, Kim YW. 2014. Quantitative measurement of elasticity of the appendix using shear wave elastography in patients with suspected acute appendicitis. PLoS One 9:e101292. http://dx.doi.org/10.1371/journal.pone.0101292.
71. Theriot CM, Koenigsknecht MJ, Carlson PE, Jr, Hatton GE, Nelson AM, Li B, Huffnagle GB, Young J Li Z, Young VB. 2014. Antibioticinduced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun 5:3114. http://dx.doi.org/10.1038/ncomms4114.
72. Razzaq R, Sukumar SA. 2006. Ultrasound diagnosis of clinically undetected Clostridium difficile toxin colitis. Clin Radiol 61:446-452. http://dx.doi.org/10.1016/j.crad.2006.01.009.
73. Chen L, Wen YM. 2011. The role of bacterial biofilm in persistent infections and control strategies. Int J Oral Sci 3:66-73. http://dx.doi.org/10.4248/IJOS11022.
74. Dawson LF, Valiente E, Faulds-Pain A, Donahue EH, Wren BW. 2012 Characterisation of Clostridium difficile biofilm formation, a role for Spo0A. PLoS One 7:e50527. http://dx.doi.org/10.1371/journal.pone.0050527.
75. Costerton JW, Stewart PS, Greenberg EP. 1999. Bacterial biofilms: a common cause of persistent infections. Science 284:1318-1322. http://dx.doi.org/10.1126/science.284.5418.1318.
76. Swidsinski A, Weber J, Loening-Baucke V, Hale LP, Lochs H. 2005. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol 43:3380-3389. http://dx.doi.org/10.1128/JCM.43.7.3380-3389.2005.
77. Kuchma SL, Delalez NJ, Filkins LM, Snavely EA, Armitage JP, O'Toole GA. 2015. Cyclic di-GMP-mediated repression of swarming motility by Pseudomonas aeruginosa PA14 requires the MotAB stator. J Bacteriol 197: 420-430. http://dx.doi.org/10.1128/JB.02130-14.
78. Huang B, Whitchurch CB, Mattick JS. 2003. FimX, a multidomain protein connecting environmental signals to twitching motility in Pseudomonas aeruginosa. J Bacteriol 185:7068-7076. http://dx.doi.org/10.1128/JB.185.24.7068-7076.2003.
79. Tamayo R, Pratt JT, Camilli A. 2007. Roles of cyclic diguanylate in the regulation of bacterial pathogenesis. Annu Rev Microbiol 61:131-148. http://dx.doi.org/10.1146/annurev.micro.61.080706.093426.